Dina Lambert Alcorn
About Dina Lambert Alcorn
Dina Lambert Alcorn is a Senior Associate Scientist at Bristol-Myers Squibb and an Associate Scientist at Juno Therapeutics, Inc., with over 20 years of experience in the biotechnology and pharmaceutical industry.
Current Positions
Dina Lambert Alcorn currently holds dual positions at Bristol-Myers Squibb and Juno Therapeutics, Inc. At Bristol-Myers Squibb, she serves as a Senior Associate Scientist in New Jersey. Concurrently, she works as an Associate Scientist at Juno Therapeutics, Inc. in Seattle, Washington. She started working at Juno Therapeutics in June 2020.
Previous Experience
Dina Lambert Alcorn has an extensive background in the biotechnology and pharmaceutical industry, with over 20 years of experience. Before her current roles, she worked at Fred Hutch as a Research Technician III from 2015 to 2016, participating in cancer research projects. Prior to that, she spent 16 years at Amgen in Thousand Oaks, California, where she contributed to various drug development projects as an Associate Scientist. Her long-term career at Amgen equipped her with a robust foundation in drug development processes.
Education and Expertise
Dina Lambert Alcorn studied at Colorado State University, where she completed a Bachelor of Science in Kinesiology, Exercise Science. Her academic background provides a strong foundation for her specialized work in cell therapy and immunotherapy research. With extensive experience in these fields, she has contributed significantly to advancements in biotechnology and pharmaceuticals.
Contributions to Cancer Research
During her tenure at Fred Hutch as a Research Technician III, Dina Lambert Alcorn was actively involved in cancer research projects. Her work contributed to critical advancements in understanding and developing treatments for cancer, a field that remains a significant focus throughout her career.
Industry Experience
Dina Lambert Alcorn has over two decades of experience in the biotechnology and pharmaceutical industries. Her roles have spanned various responsibilities, including drug development at Amgen and research science at Juno Therapeutics, Inc., and Bristol-Myers Squibb. Her expertise in cell therapy and immunotherapy has been a notable part of her professional portfolio, illustrating a comprehensive understanding of cutting-edge biotechnological advancements.